ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,975.38
0.55%
US Tech 100
20,971.60
-0.05%
다우존스 지수
42,706.56
0.00%
Bitcoin
100,852.98
-1.40%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) 뉴스

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IONS
일자시간출처헤드라인심볼기업
2025/01/0707:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2025/01/0706:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2706:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2104:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/12/2008:28PR Newswire (US)TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1510:34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1507:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1322:55Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/1306:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0900:52Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0721:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0706:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0701:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0621:01PR Newswire (US)Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman SyndromeNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0621:00PR Newswire (US)Ionis reports third quarter 2024 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
2024/11/0423:44PR Newswire (US)Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAENASDAQ:IONSIonis Pharmaceuticals Inc
2024/10/2320:05PR Newswire (US)Ionis to hold third quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
2024/10/2115:08PR Newswire (US)WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:IONS

최근 히스토리

NYSE
VZ
Verizon Communications
NASDAQ
AMZN
Amazon.com
NYSE
CVX
Chevron
NYSE
MCD
McDonalds
AMEX
XLF
Financial Select Sector
USOTC
RHHBY
Roche (QX)
COIN
DOGEUSD
Dogecoin
PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
COIN
XRPUSD
Ripple
NASDAQ
MSFT
Microsoft
CCOM
US500
US 500
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유